Form SC TO-T
KITE PHARMA, INC. filed this Form SC TO-T on 09/05/2017
Document Outline
Entire Document (1011.7 KB)
Subdocument 1 - SC TO-T - SC TO-T
Page 1 - UNITED STATES
Page 2 - ITEM 1. SUMMARY TERM SHEET.
Page 3 - ITEM 6. PURPOSES OF THE TRANSACTION AND PLANS OR PROPOSALS.
Page 4 - N/A
Page 5 - ITEM 13. INFORMATION REQUIRED BY SCHEDULE 13E-3.
Page 6 - SIGNATURE
Page 7 - EXHIBIT INDEX
Page 8 - N/A
Page 9 - N/A
Subdocument 2 - EX-99.1(A)(1)(A) - EX-99.1(A)(1)(A)
Page 1 - Exhibit (a)(1)(A)
Page 2 - IMPORTANT
Page 3 - TABLE OF CONTENTS
Page 4 - SUMMARY TERM SHEET
Page 5 - WHY IS PURCHASER MAKING THE OFFER?
Page 6 - DO YOU HAVE FINANCIAL RESOURCES TO MAKE PAYMENTS IN THE OFFER?
Page 7 - UNTIL WHAT TIME CAN I WITHDRAW PREVIOUSLY TENDERED SHARES?
Page 8 - IF THE OFFER IS COMPLETED, WILL KITE CONTINUE AS A PUBLIC COMPANY?
Page 9 - IF I ACCEPT THE OFFER, WHEN AND HOW WILL I GET PAID?
Page 10 - WHAT ARE THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE OFFER AND THE MERGER?
Page 11 - To All Holders of Shares of
Page 12 - Purchaser and Parent have the right to waive certain of the conditions to the Offer in their sole di
Page 13 - This Offer to Purchase and the related Letter of Transmittal contain important information and both
Page 14 - THE TENDER OFFER
Page 15 - N/A
Page 16 - 2. Acceptance for Payment and Payment for Shares.
Page 17 - Book-Entry Transfer.
Page 18 - THE METHOD OF DELIVERY OF SHARES, THE LETTER OF TRANSMITTAL AND ALL OTHER REQUIRED DOCUMENTS, INCLUD
Page 19 - Binding Agreement.
Page 20 - 4. Withdrawal Rights.
Page 21 - 5. U.S. Federal Income Tax Consequences of the Offer and the Merger.
Page 22 - 6. Price Range of Shares; Dividends.
Page 23 - 7. Possible Effects of the Offer on the Market for the Shares; NASDAQ Listing; Exchange Act Registra
Page 24 - Margin Regulations.
Page 25 - Sources of Information.
Page 26 - Available Information.
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - 11. Purpose of the Offer and Plans for Kite; Summary of the Merger Agreement and Certain Other Agree
Page 32 - Summary of the Merger Agreement.
Page 33 - The Offer.
Page 34 - The Merger.
Page 35 - Treatment of Equity Awards.
Page 36 - N/A
Page 37 - N/A
Page 38 - Access to Information.
Page 39 - N/A
Page 40 - Antitrust Laws.
Page 41 - N/A
Page 42 - Employee Matters.
Page 43 - ESPP.
Page 44 - Reasonable Best Efforts.
Page 45 - Takeover Laws.
Page 46 - No Solicitation.
Page 47 - bona fide
Page 48 - bona fide
Page 49 - N/A
Page 50 - N/A
Page 51 - Termination.
Page 52 - Effect of Termination.
Page 53 - Specific Performance.
Page 54 - de minimis
Page 55 - 14. Dividends and Distributions.
Page 56 - Antitrust.
Page 57 - Stockholder Approval Not Required.
Page 58 - Appraisal Rights.
Page 59 - entitled to exercise appraisal rights with respect to your Shares but, instead, subject to the condi
Page 60 - No person has been authorized to give any information or make any representation on behalf of Parent
Page 61 - SCHEDULE A
Page 62 - 2. Directors and Executive Officers of Gilead
Page 63 - N/A
Page 64 - N/A
Page 65 - N/A
Page 66 - N/A
Page 67 - N/A
Page 68 - N/A
Subdocument 3 - EX-99.1(A)(1)(B) - EX-99.1(A)(1)(B)
Page 1 - Exhibit (a)(1)(B)
Page 2 - Delivery of documents to DTC
Page 3 - NOTE: SIGNATURES MUST BE PROVIDED BELOW.
Page 4 - N/A
Page 5 - IMPORTANT
Page 6 - INSTRUCTIONS
Page 7 - Inadequate Space.
Page 8 - Special Payment and Delivery Instructions.
Page 9 - You are urged to contact the Transfer Agent immediately in order to receive further instructions and
Page 10 - Print or type
Page 11 - Note.
Page 12 - Line 2
Page 13 - Exempt payee code
Page 14 - The Depositary for the Offer is:
Subdocument 4 - EX-99.1(A)(1)(C) - EX-99.1(A)(1)(C)
Page 1 - Exhibit (a)(1)(C)
Page 2 - The Eligible Institution that completes this Notice of Guaranteed Delivery must communicate the guar
Page 3 - Notice of Guaranteed Delivery
Page 4 - GUARANTEE
Page 5 - N/A
Subdocument 5 - EX-99.1(A)(1)(D) - EX-99.1(A)(1)(D)
Page 1 - Exhibit (a)(1)(D)
Page 2 - We urge you to contact your clients as promptly as possible. Please note that the Offer and withdraw
Page 3 - Nothing contained herein or in the enclosed documents shall render you the agent of Parent, Purchase
Subdocument 6 - EX-99.1(A)(1)(E) - EX-99.1(A)(1)(E)
Page 1 - Exhibit (a)(1)(E)
Page 2 - Your prompt action is requested. Your Instruction Form should be forwarded to us in ample time to pe
Page 3 - INSTRUCTION FORM
Page 4 - recommended. In all cases, sufficient time should be allowed to ensure timely by the Expiration Date
Page 5 - N/A
Subdocument 7 - EX-99.1(A)(1)(F) - EX-99.1(A)(1)(F)
Page 1 - Exhibit (a)(1)(F)
Page 2 - After careful consideration, the Kite board of directors has, subject to the terms and upon the cond
Page 3 - with respect to the Offer.
NASDAQ (US Dollar)
$83.27
 Stock is Up 0.65 (0.79%)
Data as of 09/22/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote
Recent Webcasts
Gilead Sciences at Morgan Stanley Global Healthcare Conference

September 11, 2017 9:55 a.m. ET
Play
Gilead Sciences at Citi’s 12th Annual Biotech Conference

September 06, 2017 11:00 a.m. ET
Play
Gilead Sciences Business Update

August 28, 2017 8:00 a.m. ET
Play